The Situation

Consider an innovative medicine approaching launch in a market where the most obvious comparators are established treatments based on older technologies.

Those comparators may be clinically relevant and familiar to decision makers. They may also create an intuitive reference point for price. But if the new medicine represents a meaningful change in treatment approach, that reference point may not fully reflect its value.

The Assumption

The natural starting point is often: these are the treatments used today, so these are the products against which the new medicine should be valued.

That can be a reasonable approach. But it can also anchor expectations before asking whether those products are truly the most relevant reference point for the innovation being introduced.

Clinical similarity, mechanism, treatment setting, patient population and the evolving competitive landscape can point toward very different comparisons.

The Possibility

The better question may be:

What comparison best reflects the value of what this medicine actually brings to patients and the healthcare system?

Sometimes the answer lies beyond the most obvious existing treatment. Emerging technologies, treatments in adjacent settings, future competitors or other innovations may provide a more appropriate way to understand the asset's value.

Changing the reference point does not change the evidence. It can change how that evidence is understood.

What Changed

Reconsidering the comparator can lead to a fundamentally different value discussion.

Rather than accepting a pricing framework anchored primarily to established treatments, teams can evaluate alternative reference points and determine whether they are clinically, economically and strategically defensible.

That may support a different pricing ambition, evidence strategy or payer narrative. It can also reveal where additional evidence or positioning is needed to make the comparison credible.

The objective is not simply to find the comparator that produces the most attractive answer. It is to identify the comparison that most appropriately reflects the innovation being valued.

The Broader Lesson

Value is never assessed in isolation. The reference point matters.

When an innovative medicine does not fit neatly within the existing treatment landscape, accepting the most obvious comparator can unnecessarily constrain what is possible.

Sometimes seeing the opportunity differently begins with asking a deceptively simple question:

Compared with what?